CryoCell International Other Stockholder Equity Over Time
| CCEL Stock | USD 6.38 0.01 0.16% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out CryoCell International Performance and CryoCell International Correlation. CryoCell |
Is Health Care Providers & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CryoCell International. If investors know CryoCell will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CryoCell International listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.625 | Dividend Share 0.25 | Earnings Share 0.05 | Revenue Per Share | Quarterly Revenue Growth 0.019 |
The market value of CryoCell International is measured differently than its book value, which is the value of CryoCell that is recorded on the company's balance sheet. Investors also form their own opinion of CryoCell International's value that differs from its market value or its book value, called intrinsic value, which is CryoCell International's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CryoCell International's market value can be influenced by many factors that don't directly affect CryoCell International's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CryoCell International's value and its price as these two are different measures arrived at by different means. Investors typically determine if CryoCell International is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CryoCell International's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Other Stockholder Equity Analysis
Compare CryoCell International and related stocks such as National HealthCare, InnovAge Holding Corp, and Pennant Group Other Stockholder Equity Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NHC | 77.9 M | 139.2 M | 154.7 M | 153.1 M | 155 M | 209.5 M | 211.5 M | 215.2 M | 219.4 M | (330.3 M) | 226.9 M | 232.2 M | 227 M | 227.6 M | 232.5 M | 138 M |
| INNV | 35.6 M | 35.6 M | 35.6 M | 35.6 M | 35.6 M | 35.6 M | 35.6 M | 35.6 M | 35.6 M | 36.1 M | 323.8 M | 327.5 M | 332.1 M | 337.4 M | 388.1 M | 255.3 M |
| PNTG | 55 M | 55 M | 55 M | 55 M | 55 M | 55 M | 55 M | 55 M | 55.9 M | 74.9 M | 84.6 M | 95.5 M | 99.7 M | 105.6 M | 236 M | 247.8 M |
| EHC | 500 K | 2.7 B | 2.7 B | 2.4 B | 2.4 B | 2.3 B | 2.2 B | 2.3 B | 2.2 B | 1.9 B | 1.8 B | 1.8 B | 1.2 B | 1.2 B | 1.3 B | 1.8 B |
| AIRS | 120.4 M | 120.4 M | 120.4 M | 120.4 M | 120.4 M | 120.4 M | 120.4 M | 120.4 M | 120.4 M | 120.4 M | 123.7 M | 83.9 M | 85.9 M | 103.9 M | 107.7 M | 83.4 M |
| AVAH | 669.4 M | 669.4 M | 669.4 M | 669.4 M | 669.4 M | 669.4 M | 669.4 M | 669.4 M | 669.4 M | 669.4 M | 721.2 M | 1.2 B | 1.2 B | 1.2 B | 1.3 B | 1.2 B |
| TOI | 94 K | 94 K | 94 K | 94 K | 94 K | 94 K | 94 K | 94 K | 94 K | 94 K | 80.4 M | 167.4 M | 186.2 M | 203.2 M | 233.6 M | 140.2 M |
| BKD | 177.4 M | 1.9 B | 2 B | 3.8 B | 4 B | 6.6 B | 6.9 B | 7.1 B | 7.1 B | 7.5 B | 4.1 B | 4.1 B | 4.2 B | 4.2 B | 4.3 B | 3.6 B |
| SGRY | 76.9 M | 76.9 M | 76.9 M | 76.9 M | 113.8 M | 386.5 M | 406.9 M | 384.4 M | 314.3 M | 268.7 M | 607.9 M | 1.6 B | 2.5 B | 2.5 B | 2.5 B | 2.6 B |
| SEM | (299 M) | 770.2 M | 790.4 M | 831.9 M | 809.1 M | 873.2 M | 956.7 M | 1.1 B | 1.2 B | 649.1 M | 509.1 M | 504.3 M | 452.2 M | 493.4 M | 911.1 M | 582.5 M |
| ENSG | 1.4 M | 74.7 M | 88.8 M | 99.7 M | 113 M | 316.5 M | 331.4 M | 371.7 M | 428.7 M | 264.6 M | 267 M | 286.7 M | 300.9 M | 349.2 M | 410.3 M | 430.8 M |
| MD | 16.2 M | 789.8 M | 862.1 M | 945 M | 983.8 M | 1 B | 1.1 B | 1.2 B | 1.2 B | 987.9 M | 1 B | 1 B | 983.6 M | 999.9 M | 1 B | 709.6 M |
| PIII | 921.1 K | 921.1 K | 921.1 K | 921.1 K | 921.1 K | 921.1 K | 921.1 K | 921.1 K | 921.1 K | 921.1 K | (10.5 M) | 315.4 M | 315.4 M | 509.4 M | 585.9 M | 615.2 M |
| SNDA | 92 M | 134.4 M | 136.9 M | 142.8 M | 150.1 M | 159 M | 168.2 M | 176 M | 184.4 M | 187 M | 189 M | 337 M | 295.3 M | 303 M | 440.8 M | 462.8 M |
| ACHC | 146.4 M | 146.4 M | 480.4 M | 491.1 M | 847.3 M | 1.6 B | 2.5 B | 2.5 B | 2.5 B | 2.6 B | 2.6 B | 2.6 B | 2.7 B | 2.6 B | 2.7 B | 2.1 B |
| DCGO | 141.7 M | 141.7 M | 141.7 M | 141.7 M | 141.7 M | 141.7 M | 141.7 M | 141.7 M | 141.7 M | 141.7 M | 142.3 M | 283.2 M | 301.5 M | 320.7 M | 322.3 T | 338.4 T |
| CCM | 1.1 B | 2.6 B | 2.5 B | 2.5 B | 2.1 B | 2.1 B | 1.9 B | 1.9 B | 1.8 B | 1.8 B | 1.8 B | 1.9 B | 1.9 B | 2 B | 1.8 B | 1.7 B |
CryoCell International and related stocks such as National HealthCare, InnovAge Holding Corp, and Pennant Group Other Stockholder Equity description
My Equities
My Current Equities and Potential Positions
| CryoCell International | CCEL |
Specialization | Health Care, Health Care Equipment & Services |
| Location | Florida; U.S.A |
| Exchange | NYSE MKT Exchange |
USD 6.38
Check out CryoCell International Performance and CryoCell International Correlation. For more information on how to buy CryoCell Stock please use our How to buy in CryoCell Stock guide.You can also try the CEOs Directory module to screen CEOs from public companies around the world.
CryoCell International technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.